| Bioactivity | Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a cytotoxic derivative of Calicheamicin, and a monoclonal antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Calicheamicin is a cytotoxic antibiotic. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia[1]. |
| Name | Gemtuzumab ozogamicin |
| CAS | 220578-59-6 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Store at 4°C, do not freeze |
| Reference | [1]. Baron J, et al. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018;11(6):549-559. |